These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23927471)

  • 1. Cellular distribution studies of the nitric oxide-generating antineoplastic prodrug O(2) -(2,4-dinitrophenyl)1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate formulated in Pluronic P123 micelles.
    Kaur I; Terrazas M; Kosak KM; Kern SE; Boucher KM; Shami PJ
    J Pharm Pharmacol; 2013 Sep; 65(9):1329-36. PubMed ID: 23927471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a Pluronic(®) P123 formulation on the nitric oxide-generating drug JS-K.
    Kaur I; Kosak KM; Terrazas M; Herron JN; Kern SE; Boucher KM; Shami PJ
    Pharm Res; 2015 Apr; 32(4):1395-406. PubMed ID: 25330743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity.
    Shami PJ; Saavedra JE; Wang LY; Bonifant CL; Diwan BA; Singh SV; Gu Y; Fox SD; Buzard GS; Citro ML; Waterhouse DJ; Davies KM; Ji X; Keefer LK
    Mol Cancer Ther; 2003 Apr; 2(4):409-17. PubMed ID: 12700285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitric oxide-releasing prodrug triggers cancer cell death through deregulation of cellular redox balance.
    Maciag AE; Holland RJ; Robert Cheng YS; Rodriguez LG; Saavedra JE; Anderson LM; Keefer LK
    Redox Biol; 2013; 1(1):115-24. PubMed ID: 24024144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of human glutathione transferases in biotransformation of the nitric oxide prodrug JS-K.
    Sjödin B; Mannervik B
    Sci Rep; 2021 Oct; 11(1):20765. PubMed ID: 34675290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JS-K, a nitric oxide prodrug, induces cytochrome c release and caspase activation in HL-60 myeloid leukemia cells.
    Udupi V; Yu M; Malaviya S; Saavedra JE; Shami PJ
    Leuk Res; 2006 Oct; 30(10):1279-83. PubMed ID: 16439016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The nitric oxide prodrug JS-K and its structural analogues as cancer therapeutic agents.
    Maciag AE; Saavedra JE; Chakrapani H
    Anticancer Agents Med Chem; 2009 Sep; 9(7):798-803. PubMed ID: 19538173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nitric oxide prodrug JS-K inhibits ubiquitin E1 and kills tumor cells retaining wild-type p53.
    Kitagaki J; Yang Y; Saavedra JE; Colburn NH; Keefer LK; Perantoni AO
    Oncogene; 2009 Jan; 28(4):619-24. PubMed ID: 18978812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, mechanistic studies, and anti-proliferative activity of glutathione/glutathione S-transferase-activated nitric oxide prodrugs.
    Chakrapani H; Kalathur RC; Maciag AE; Citro ML; Ji X; Keefer LK; Saavedra JE
    Bioorg Med Chem; 2008 Nov; 16(22):9764-71. PubMed ID: 18930407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells.
    Simeone AM; McMurtry V; Nieves-Alicea R; Saavedra JE; Keefer LK; Johnson MM; Tari AM
    Breast Cancer Res; 2008; 10(3):R44. PubMed ID: 18474097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The nitric oxide donor JS-K sensitizes U87 glioma cells to repetitive irradiation.
    Heckler M; Osterberg N; Guenzle J; Thiede-Stan NK; Reichardt W; Weidensteiner C; Saavedra JE; Weyerbrock A
    Tumour Biol; 2017 Jun; 39(6):1010428317703922. PubMed ID: 28653883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/NO and Double JS-K, through incorporation into PEG-protected nanoparticles.
    Kumar V; Hong SY; Maciag AE; Saavedra JE; Adamson DH; Prud'homme RK; Keefer LK; Chakrapani H
    Mol Pharm; 2010 Feb; 7(1):291-8. PubMed ID: 20000791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JS-K, an arylating nitric oxide (NO) donor, has synergistic anti-leukemic activity with cytarabine (ARA-C).
    Shami PJ; Maciag AE; Eddington JK; Udupi V; Kosak KM; Saavedra JE; Keefer LK
    Leuk Res; 2009 Nov; 33(11):1525-9. PubMed ID: 19193435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of JS-K [O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and related O2-aryl diazeniumdiolates in vitro and in vivo.
    Shami PJ; Saavedra JE; Bonifant CL; Chu J; Udupi V; Malaviya S; Carr BI; Kar S; Wang M; Jia L; Ji X; Keefer LK
    J Med Chem; 2006 Jul; 49(14):4356-66. PubMed ID: 16821795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and evaluation of piperazine and homopiperazine analogues of JS-K, an anti-cancer lead compound.
    Nandurdikar RS; Maciag AE; Citro ML; Shami PJ; Keefer LK; Saavedra JE; Chakrapani H
    Bioorg Med Chem Lett; 2009 May; 19(10):2760-2. PubMed ID: 19364650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Nitric Oxide Prodrug JS-K Induces Ca(2+)-Mediated Apoptosis in Human Hepatocellular Carcinoma HepG2 Cells.
    Liu L; Wang D; Wang J; Wang S
    J Biochem Mol Toxicol; 2016 Apr; 30(4):192-9. PubMed ID: 26616367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo.
    Kiziltepe T; Anderson KC; Kutok JL; Jia L; Boucher KM; Saavedra JE; Keefer LK; Shami PJ
    J Pharm Pharmacol; 2010 Jan; 62(1):145-51. PubMed ID: 20723011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation.
    Liu J; Li C; Qu W; Leslie E; Bonifant CL; Buzard GS; Saavedra JE; Keefer LK; Waalkes MP
    Mol Cancer Ther; 2004 Jun; 3(6):709-14. PubMed ID: 15210857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The nitric oxide prodrug JS-K is effective against non-small-cell lung cancer cells in vitro and in vivo: involvement of reactive oxygen species.
    Maciag AE; Chakrapani H; Saavedra JE; Morris NL; Holland RJ; Kosak KM; Shami PJ; Anderson LM; Keefer LK
    J Pharmacol Exp Ther; 2011 Feb; 336(2):313-20. PubMed ID: 20962031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JS-K as a nitric oxide donor induces apoptosis via the ROS/Ca
    Huang Z; Liu L; Chen J; Cao M; Wang J
    Biomed Pharmacother; 2018 Nov; 107():1385-1392. PubMed ID: 30257354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.